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Commentary Commentary Commentary Commentary Commentary
Stimulating the Development of Orphan
(and Other) Vaccines
Drs. Lang and Wood (this issue, pp. 749-756)
highlight factors that affect vaccine development
decisions at large pharmaceutical companies and
suggest measures to make development of
orphan vaccines more attractive.  Because of the
importance of economic assessment in corporate
decision-making, development of vaccines for
rare diseases is usually problematic. Exceptions
may include vaccines for potential bioterrorism
agents (the government may support develop-
ment and production) and therapeutic vaccines
for chronic or deadly diseases (the price of a
vaccine could be high, commensurate with the
cost of therapy).  Of seven vaccines defined by the
Institute of Medicine as being “most favorable”
for development, three were therapeutic vac-
cines (for diabetes mellitus, rheumatoid arthri-
tis, and multiple sclerosis) (1).
In the developing world, price has been a
major impediment to the introduction of new
vaccines.  Whether this reflects limitations in
ability or willingness to pay, the end result is
that a company could not expect sales in
developing countries to provide the desired
return on investment (2). Clearly, novel solutions
are needed if vaccines that could save millions of
children’s lives are to be used effectively.  Support
for vaccination from the Bill and Melinda Gates
Foundation and the promotion of vaccines as an
acceptable component of bilateral loans by the
World Bank may begin shifting the balance
between market imperatives and public health needs.
Drs. Lang and Wood propose a package of
incentives that may help promote development
of orphan vaccines by major manufacturers. But
will these measures be enough to alter vaccine
development priorities?  Lowering the risks or
costs of vaccine development may be much less
important than increasing the potential for
profit.  The vaccine development pipeline is full
of products that will never come to market, not
because they cost more to develop but because
the company projects insufficient profit from
their eventual use. Promoting a greater
appreciation of the benefits of prevention in both
developing and industrialized countries and
enhancing the size of the market and the
willingness to pay will likely have a greater impact
on investment decisions than an incremental
decrease in vaccine development costs.
If large manufacturers shift vaccine develop-
ment priorities on the basis of incentives and
other measures so that the total number of
products brought to market is not increased but
one set of priorities is substituted for another,
the overall impact on disease prevention may be
not change.  The greatest increase in disease
prevention and in the development of orphan
vaccines would occur by increasing the total
number of vaccines produced.  The therapeutics
industry differs from the vaccine industry in that
it includes a substantially greater number of
players that can bring a new product to market.
In the United States currently, 194 drugs and
biologics have been brought to market as orphan
products, but none are vaccines. Thus, incen-
tives that draw new companies to invest in
vaccine development may be extremely useful
for the development of orphan vaccines.
Vaccines prevent more than 3.2 million
deaths per year (3). Developments in biotechnol-
ogy have created the promise of prevention for
many more infectious and chronic diseases (4).
Realizing this promise will require bringing to
licensure more of the vaccines now in
development. Finally, our credibility in designat-
ing disease areas as priorities for vaccine
development rests on our ability to use the new
vaccines already in hand.
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